Gerber Kawasaki Wealth & Investment Management Purchases 110 Shares of Johnson & Johnson (NYSE:JNJ)

Gerber Kawasaki Wealth & Investment Management lifted its position in Johnson & Johnson (NYSE:JNJ) by 3.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 3,082 shares of the company’s stock after acquiring an additional 110 shares during the period. Gerber Kawasaki Wealth & Investment Management’s holdings in Johnson & Johnson were worth $446,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Rinkey Investments lifted its stake in Johnson & Johnson by 35.2% in the fourth quarter. Rinkey Investments now owns 4,377 shares of the company’s stock worth $633,000 after purchasing an additional 1,140 shares during the last quarter. Aquatic Capital Management LLC raised its holdings in shares of Johnson & Johnson by 914.7% in the fourth quarter. Aquatic Capital Management LLC now owns 64,938 shares of the company’s stock worth $9,391,000 after buying an additional 58,538 shares during the period. Oxford Asset Management LLP lifted its stake in shares of Johnson & Johnson by 257.8% during the 4th quarter. Oxford Asset Management LLP now owns 12,219 shares of the company’s stock worth $1,767,000 after acquiring an additional 8,804 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in Johnson & Johnson by 0.5% during the 4th quarter. Coldstream Capital Management Inc. now owns 48,436 shares of the company’s stock valued at $7,005,000 after acquiring an additional 252 shares during the period. Finally, Capital Analysts LLC increased its stake in Johnson & Johnson by 1.4% in the fourth quarter. Capital Analysts LLC now owns 43,027 shares of the company’s stock worth $6,223,000 after purchasing an additional 580 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $154.54 on Friday. The stock’s 50-day moving average is $159.48 and its 200 day moving average is $154.84. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $371.83 billion, a P/E ratio of 23.24, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Barclays lowered their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Leerink Partners reduced their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $171.82.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.